These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33474634)
1. Advances in anti-BRAF therapies for lung cancer. Roviello G; D'Angelo A; Sirico M; Pittacolo M; Conter FU; Sobhani N Invest New Drugs; 2021 Jun; 39(3):879-890. PubMed ID: 33474634 [TBL] [Abstract][Full Text] [Related]
2. Targeting Baik CS; Myall NJ; Wakelee HA Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464 [TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
4. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker. Turshudzhyan A; Vredenburgh J Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186 [TBL] [Abstract][Full Text] [Related]
5. Clinical Development of BRAF plus MEK Inhibitor Combinations. Subbiah V; Baik C; Kirkwood JM Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065 [TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930 [TBL] [Abstract][Full Text] [Related]
8. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867 [TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735 [TBL] [Abstract][Full Text] [Related]
10. Crizotinib resistance: BRAF mutation implications for therapeutic strategies. Xie L Cancer Treat Res Commun; 2021; 28():100391. PubMed ID: 34004505 [TBL] [Abstract][Full Text] [Related]
11. [Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors]. Kang X; Zhu N; Song X Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):711-714. PubMed ID: 27760604 [TBL] [Abstract][Full Text] [Related]
12. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer]. Deng L; Yang Y; Huang J Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628 [TBL] [Abstract][Full Text] [Related]
13. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
14. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D; Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D; Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537 [TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V Metzenmacher M; Goetz M; Herold T; Stuschke M; Aigner C; Darwiche K; Eberhardt WE; Schuler M; Wiesweg M Clin Lung Cancer; 2021 Sep; 22(5):e668-e672. PubMed ID: 33551244 [No Abstract] [Full Text] [Related]